The Oncology InstituteTOI
TOI
About: The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.
Employees: 825
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
367% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 3
318% more capital invested
Capital invested by funds: $4.61M [Q4 2024] → $19.3M (+$14.7M) [Q1 2025]
35% more funds holding
Funds holding: 31 [Q4 2024] → 42 (+11) [Q1 2025]
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
2.84% more ownership
Funds ownership: 19.47% [Q4 2024] → 22.31% (+2.84%) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for TOI.
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
The Oncology Institute set to join the Russell 2000® and Russell 3000® Indexes
CERRITOS, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that it will join the Russell 2000® and Russell 3000® after the 2025 Russell indexes annual reconstitution, effective after the US market closes on June 27, according to a preliminary list of additions posted on May 23.
Neutral
Seeking Alpha
1 month ago
The Oncology Institute, Inc. (TOI) Q1 2025 Earnings Call Transcript
The Oncology Institute, Inc. (NASDAQ:TOI ) Q1 2025 Earnings Conference Call May 14, 2025 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - Chief Executive Officer Rob Carter - Chief Financial Officer Conference Call Participants David Larsen - BTIG Yuan Zhi - B. Riley Bill Sutherland - The Benchmark Company Robert LeBoyer - NOBLE Capital Markets Operator Good afternoon and welcome to The Oncology Institute's First Quarter 2025 Earnings Conference Call.
Neutral
GlobeNewsWire
1 month ago
The Oncology Institute Welcomes Dr. Jeff Langsam as Chief Clinical Officer
CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that Dr. Jeffrey Langsam will assume the role of enterprise Chief Clinical Officer effective May 13th, 2025. The CCO role will oversee therapeutics including pathway and procurement decisions, utilization management, and MSO practice clinical engagement. Dr. Langsam joins TOI from Cigna Healthcare, where he was the National Director of Oncology and a Senior Medical Director in the Specialty Pharmacy Division. He previously served as a Regional Medical Director at Aetna, and was clinical faculty at the University of Connecticut where he was a practicing oncologist for many years.
Neutral
GlobeNewsWire
1 month ago
The Oncology Institute to Participate at the B. Riley Securities 25th Annual Institutional Investor Conference
CERRITOS, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in B. Riley's 25th Annual Institutional Investor Conference in Marina Del Rey, CA on May 21st, 2025.
Neutral
GlobeNewsWire
1 month ago
The Oncology Institute Announces First Quarter 2025 Earnings Release Date and Conference Call
CERRITOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its first quarter 2025 financial results after the market close on Wednesday, May 14, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).
Neutral
GlobeNewsWire
2 months ago
TOI Launches Florida Oncology Network, a Fully Delegated Cancer Care Network, and Announces Four Additional Value-based Contracts in Q1
CERRITOS, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today proudly announced the launch of the Florida Oncology Network. This new fully delegated network will expand access to high-quality, coordinated cancer care for Florida residents.
Neutral
Seeking Alpha
2 months ago
The Oncology Institute, Inc. (TOI) Q4 2024 Earnings Call Transcript
The Oncology Institute, Inc. (NASDAQ:TOI ) Q4 2024 Earnings Conference Call March 25, 2025 5:00 PM ET Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - CEO Rob Carter - CFO Conference Call Participants Yuan Zhi - B. Riley Robert LeBoyer - NOBLE Capital Markets Operator Good afternoon, and welcome to The Oncology Institute's Fourth Quarter and Full-Year 2024 Earnings Conference Call.
Neutral
GlobeNewsWire
2 months ago
The Oncology Institute Reports Fourth Quarter and Full Year 2024 Financial Results and Guidance for 2025
CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its fourth quarter and year ended December 31, 2024.
Neutral
GlobeNewsWire
2 months ago
The Oncology Institute Announces $16.5 million Private Placement
CERRITOS, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with accredited investors for a private placement that is expected to result in gross proceeds of approximately $16.5 million, before deducting placement agent fees and offering expenses (the “Private Placement”). The Private Placement includes participation from existing investors, as well as members of the Company's management team and Board of Directors and is expected to close on March 26, 2025, subject to customary closing conditions.
Neutral
GlobeNewsWire
3 months ago
The Oncology Institute Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Conference Call
CERRITOS, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its fourth quarter and full year 2024 financial results after the market close on Tuesday, March 25, 2025, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time).
Charts implemented using Lightweight Charts™